Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.740
+0.100 (2.16%)
Jun 24, 2025, 4:00 PM - Market closed
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Monte Rosa Therapeutics stock have a consensus rating of "Buy" and an average price target of $14.33, which forecasts a 202.32% increase in the stock price over the next year. The lowest target is $10 and the highest is $17.
Price Target: $14.33 (+202.32%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $10 | Hold | Maintains | $11 → $10 | +110.97% | Mar 21, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +258.65% | Mar 21, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | +132.07% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +132.07% | Sep 12, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +258.65% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
112.69M
from 75.62M
Increased by 49.02%
Revenue Next Year
44.78M
from 112.69M
Decreased by -60.26%
EPS This Year
-0.57
from -0.98
EPS Next Year
-1.47
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 144.8M | 180.6M | 270.9M | ||
| Avg | 112.7M | 44.8M | 56.0M | ||
| Low | 83.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 91.5% | 60.3% | 505.0% | ||
| Avg | 49.0% | -60.3% | 25.0% | ||
| Low | 10.2% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.04 | -0.17 | 0.18 | ||
| Avg | -0.57 | -1.47 | -1.46 | ||
| Low | -0.89 | -2.10 | -2.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.